The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study (Q51943315)

From Wikidata

Jump to navigation Jump to search

scientific article published in May 2006

Language	Label	Description	Also known as
English	The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study	scientific article published in May 2006

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

18 April 2018

http://europepmc.org/abstract/MED/16630034

The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study (English)

1 reference

Europe PubMed Central

PubMed publication ID

18 April 2018

http://europepmc.org/abstract/MED/16630034

0 references

myocardial infarction

1 reference

based on heuristic

inferred from title

13

1 reference

Europe PubMed Central

PubMed publication ID

18 April 2018

http://europepmc.org/abstract/MED/16630034

Rodolphe Thiébaut

7

object named as

R Thiébaut

1 reference

Europe PubMed Central

PubMed publication ID

18 April 2018

http://europepmc.org/abstract/MED/16630034

Antonella d'Arminio Monforte

6

object named as

A D'Arminio Monforte

1 reference

Europe PubMed Central

PubMed publication ID

18 April 2018

http://europepmc.org/abstract/MED/16630034

D:A:D study group

16

object named as

D:A:D Study Group

1 reference

Europe PubMed Central

PubMed publication ID

18 April 2018

http://europepmc.org/abstract/MED/16630034

15

object named as

J D Lundgren

1 reference

Europe PubMed Central

PubMed publication ID

18 April 2018

http://europepmc.org/abstract/MED/16630034

12

object named as

O Kirk

1 reference

Europe PubMed Central

PubMed publication ID

18 April 2018

http://europepmc.org/abstract/MED/16630034

5

object named as

P Reiss

1 reference

Europe PubMed Central

PubMed publication ID

18 April 2018

http://europepmc.org/abstract/MED/16630034

author name string

M G Law

1

1 reference

Europe PubMed Central

PubMed publication ID

18 April 2018

http://europepmc.org/abstract/MED/16630034

N Friis-Møller

2

1 reference

Europe PubMed Central

PubMed publication ID

18 April 2018

http://europepmc.org/abstract/MED/16630034

W M El-Sadr

3

1 reference

Europe PubMed Central

PubMed publication ID

18 April 2018

http://europepmc.org/abstract/MED/16630034

R Weber

4

1 reference

Europe PubMed Central

PubMed publication ID

18 April 2018

http://europepmc.org/abstract/MED/16630034

L Morfeldt

8

1 reference

Europe PubMed Central

PubMed publication ID

18 April 2018

http://europepmc.org/abstract/MED/16630034

S De Wit

9

1 reference

Europe PubMed Central

PubMed publication ID

18 April 2018

http://europepmc.org/abstract/MED/16630034

C Pradier

10

1 reference

Europe PubMed Central

PubMed publication ID

18 April 2018

http://europepmc.org/abstract/MED/16630034

G Calvo

11

1 reference

Europe PubMed Central

PubMed publication ID

18 April 2018

http://europepmc.org/abstract/MED/16630034

A N Phillips

14

1 reference

Europe PubMed Central

PubMed publication ID

18 April 2018

http://europepmc.org/abstract/MED/16630034

publication date

1 May 2006

1 reference

Europe PubMed Central

PubMed publication ID

18 April 2018

http://europepmc.org/abstract/MED/16630034

1 reference

Europe PubMed Central

PubMed publication ID

18 April 2018

http://europepmc.org/abstract/MED/16630034

7

1 reference

Europe PubMed Central

PubMed publication ID

18 April 2018

http://europepmc.org/abstract/MED/16630034

4

1 reference

Europe PubMed Central

PubMed publication ID

18 April 2018

http://europepmc.org/abstract/MED/16630034

218-230

1 reference

Europe PubMed Central

PubMed publication ID

18 April 2018

http://europepmc.org/abstract/MED/16630034

A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00362.X

21 January 2018

Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00362.X

21 January 2018

Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00362.X

21 January 2018

Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00362.X

21 January 2018

Prediction of Coronary Heart Disease Using Risk Factor Categories

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00362.X

21 January 2018

Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00362.X

21 January 2018

Combination antiretroviral therapy and the risk of myocardial infarction

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00362.X

21 January 2018

Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection?

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00362.X

21 January 2018

Cardiovascular disease risk profiles.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00362.X

21 January 2018

Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00362.X

21 January 2018

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00362.X

21 January 2018

European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00362.X

21 January 2018

Updated guidelines for cholesterol management

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00362.X

21 January 2018

Drug therapy for coronary heart disease: the Sheffield table

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00362.X

21 January 2018

Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00362.X

21 January 2018

Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00362.X

21 January 2018

Modelling the 3-year risk of myocardial infarction among participants in the Data Collection on Adverse Events of Anti-HIV Drugs (DAD) study.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00362.X

21 January 2018

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00362.X

21 January 2018

Prediction of coronary heart disease: a comparison between the Copenhagen risk score and the Framingham risk score applied to a Dutch population

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00362.X

21 January 2018

A cross-validation of risk-scores for coronary heart disease mortality based on data from the Glostrup Population Studies and Framingham Heart Study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00362.X

21 January 2018

Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA project populations. Monitoring trends and determinants in cardiovascular disease.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00362.X

21 January 2018

Hypofibrinolytic state in HIV-1-infected patients treated with protease inhibitor-containing highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00362.X

21 January 2018

Prevalence and prognosis of electrocardiographic left ventricular hypertrophy, ST segment depression and negative T-wave; the Copenhagen City Heart Study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00362.X

21 January 2018

Efficacy and safety of fluvastatin in hyperlipidemic protease inhibitor-treated HIV-infected patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00362.X

21 January 2018

Efficacy and tolerability of pravastatin for the treatment of HIV-1 protease inhibitor-associated hyperlipidaemia: a pilot study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00362.X

21 January 2018

Mechanisms of plaque stabilization with statins

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00362.X

21 January 2018

Estimation of contribution of changes in classic risk factors to trends in coronary-event rates across the WHO MONICA Project populations

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00362.X

21 January 2018

Coronary heart disease incidence in northern and southern European populations: a reanalysis of the seven countries study for a European coronary risk chart

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00362.X

21 January 2018

Are the Framingham and PROCAM coronary heart disease risk functions applicable to different European populations? The PRIME Study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00362.X

21 January 2018

Protease inhibitors and cardiovascular outcomes in patients with HIV-1

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00362.X

21 January 2018

Guidelines for the Evaluation and Management of Dyslipidemia in Human Immunodeficiency Virus (HIV)-Infected Adults Receiving Antiretroviral Therapy: Recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00362.X

21 January 2018

Identifiers

10.1111/J.1468-1293.2006.00362.X

1 reference

Europe PubMed Central

PubMed publication ID

18 April 2018

http://europepmc.org/abstract/MED/16630034

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

18 April 2018

http://europepmc.org/abstract/MED/16630034

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51943315&oldid=2285887655"